肝脾联合切除对肝癌合并门脉高压、脾亢治疗效果的临床观察  

Clinical observation by anatomical liver resection and splenectomy on patients with primary hepatocellular carcinoma, portal hypertension and hypersplenism

作　　者：苏军昌 王惠楠 

机构地区：[1]兰州市第二人民医院普外一科,甘肃兰州730046 [2]甘肃省第二人民医院消化科,甘肃兰州730000

出　　处：《甘肃医药》2013年第10期726-728,共3页Gansu Medical Journal

摘　　要：目的:观察解剖性肝切除联合脾切除对肝癌合并门脉高压并脾亢的治疗效果,探讨其临床意义。方法:收集我院确诊为肝癌合并门脉高压并脾亢的80例患者。依患者的入院顺序分为两组,观察组共40例,应用解剖性肝切除联合脾切除进行治疗;对照组共40例,应用传统治疗联合脾切除进行治疗。观察相关临床特征的差别。结果:两组患者均顺利完成手术,观察组患者术中出血量及围手术期的输血量明显低于对照组。观察组脾亢改善明显,观察组术后2年生存率明显高于对照组,观察组术后2年生活质量明显高于对照组。结论:解剖性肝切除联合脾切除对肝癌合并门脉高压、脾亢患者的治疗效果理想,并可提高术后的生存率及生活质量。Objective： To study the clinical effect in patients with primary hepatocellular carcinom, portal hypertension and hypersplenism by anatomical liver resection and splenectomy surgery, and investigate the clinical significance. Methods： 80 cases with primary hepatocellular carcinom, portal hypertension and hypersplenism were observed and divided into two groups. The control group（40 cases） were treated by traditional treatment and splenectomy, the observation group （40 cases） were treated by anatomical liver resection and splenectomy in which the clinical index were observed in the two group. Results： The surgery were completed successfully in the two group in which the intraoperative blood loss and transfusion volume were less in the observation group than that in the control group. The hypersplenism was improved in the two group and the survival rate and life quality were higher in the observation group than that in the control group. Conclusion： The surgery treatment of anatomical liver resection and splenectomy can increase the clinical effect, improve the survival rate and life quality in patients with hepatocellular carcinoma, portal hypertension and hypersplenism.

关 键 词：解剖性肝切除 脾切除 肝癌 门脉高压 生活质量 

分 类 号：R657.34[医药卫生—外科学]